Skip to content

RNTX RNTX Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$1.56B-57.1%
Gilead Sciences logo
Gilead SciencesGILD
-$4.24B-23.7%
AbbVie logo
AbbVieABBV
$919M+173%
CTO
Citius Oncology, Inc.CTOR
$15.13M+299%
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
-$142K-101%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$21K-98.4%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's financing cash flow?
RNTX (RNTX) reported financing cash flow of $4.65M in Q1 2026.
How has RNTX's financing cash flow changed year-over-year?
RNTX's financing cash flow increased by 530.6% year-over-year, from $738K to $4.65M.
What is the long-term trend for RNTX's financing cash flow?
Over 2 years (2021 to 2025), RNTX's financing cash flow has grown at a -58.1% compound annual growth rate (CAGR), from $55.66M to $9.76M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.